According to reporting from NPR, drawing on provisional data from federal health agencies, COVID-19 fell out of the top 10 leading causes of death in the United States in 2024. It is a milestone that would have been hard to imagine during the pandemic’s early years, when the virus surged to become the nation’s third-leading killer in 2020 and 2021 and remained a major driver of mortality in 2022. The new ranking reflects a substantial and sustained decline in severe outcomes, even as the virus settles into an endemic pattern with periodic waves.

The development signals both progress and complexity. On one hand, it suggests that layers of population immunity from vaccination and prior infection, along with better clinical care and antivirals, have reduced the average severity of illness. On the other hand, the virus continues to cause tens of thousands of deaths annually, especially among older adults and people with underlying conditions, and it contributes to ongoing morbidity through long COVID. In short: falling out of the top 10 does not mean COVID-19 has become inconsequential, but it does indicate a new phase.

What changed in 2024?

• Population immunity deepened: After multiple vaccination campaigns and repeated exposures to evolving variants, far more Americans now carry some level of immune protection against severe disease. While immunity wanes over time and new variants can escape parts of the immune response, baseline protection against hospitalization and death remains markedly higher than early in the pandemic.
• Better tools and care: Antivirals (such as nirmatrelvir-ritonavir), monoclonal antibodies when effective, improved inpatient protocols, and earlier testing and treatment have all contributed to fewer severe outcomes. Clinicians are also more adept at managing COVID-related complications.
• Shifts in viral dynamics: Successive Omicron-lineage variants have tended to be more transmissible but, on average, less likely to cause severe lower-respiratory disease compared with earlier strains, particularly in immunized individuals. That shift, combined with prior immunity, has “decoupled” case surges from the scale of hospitalizations and deaths seen in 2020–2021.
• Behavioral adaptations: Many people continue informal risk management—testing before visiting vulnerable relatives, staying home when sick, improving ventilation, or masking in high-risk settings—actions that cumulatively blunt transmission to those most at risk.

Together, these factors have pushed COVID-19 mortality down relative to other entrenched health threats, even as the virus remains a seasonal presence with winter spikes and smaller off-season bumps.

How “leading causes of death” are determined

The ranking of leading causes of death in the U.S. is based on standardized categories and counts of death certificates that list an “underlying cause,” not merely a contributing factor. This matters for COVID-19, which can worsen other conditions—like heart or lung disease—without always being coded as the singular underlying cause. As a result, the virus’s total impact on mortality can be larger than its rank alone suggests.

Provisional data are also subject to reporting lags and later revision. Final annual rankings are confirmed after states complete death certificate processing and the National Center for Health Statistics finalizes the data. Still, provisional rankings are widely used for timely public health insight and typically track closely with finalized results.

In recent years, the country’s top causes of death have typically included heart disease and cancer at the top, followed by unintentional injuries (such as overdoses and motor vehicle crashes), chronic lower respiratory diseases, stroke, Alzheimer’s disease, diabetes, kidney disease, and others. COVID-19’s drop below these categories in 2024 marks a return toward the pre-pandemic profile—albeit with the virus still present in the background.

What this milestone does—and doesn’t—mean

• It’s real progress, not an endpoint: Fewer deaths is unequivocally good news. But progress can reverse if a more immune-evasive variant emerges, if immunization rates fall, or if access to treatments declines.
• Risks are not evenly distributed: Older adults, people with chronic conditions (such as heart, lung, kidney disease, diabetes), individuals who are immunocompromised, and those facing structural barriers to care remain at heightened risk. Many of the remaining deaths are concentrated in these groups.
• Long COVID persists: Even when not fatal, infections can produce prolonged symptoms affecting work and quality of life. Lower fatality does not eliminate the need to reduce infections in vulnerable settings.
• Seasonality still matters: Winter surges driven by indoor crowding and waning immunity can temporarily elevate COVID-19’s rank regionally or nationally. A year-end spike could shift provisional positions, though large reversals have become less likely.

Why vaccination and timely treatment still count

The same tools that helped drive COVID-19 down the mortality rankings remain the best defenses. Updated vaccines restore protection that wanes over time and broaden coverage against circulating variants. Early testing enables prompt access to antivirals, which are most effective when started quickly after symptom onset. In high-risk settings—long-term care facilities, crowded indoor venues, and poorly ventilated workplaces—layered strategies like improving airflow and staying home when sick further reduce transmission.

Public health officials emphasize that these measures are not about eliminating risk entirely, but about keeping severe outcomes rare and protecting people most likely to be harmed. Maintaining access to testing and treatment, ensuring vaccine availability and uptake, and supporting sick leave policies are practical steps that help sustain the gains seen in 2024.

Equity and access remain central

The burden of COVID-19 has not been evenly shared. Communities with higher rates of chronic disease, less access to primary care, and greater exposure risk due to work and housing conditions have experienced disproportionate impacts. Continued progress depends on closing gaps in vaccination, treatment access, and preventive resources. Investments in community health workers, mobile and pharmacy-based services, and multilingual outreach have proven effective and merit ongoing support.

The bigger picture: A shifting landscape of U.S. mortality

The U.S. continues to grapple with other urgent drivers of death and life expectancy, including cardiovascular disease, cancer, the drug overdose crisis, firearm injuries, and chronic illnesses tied to metabolic and respiratory health. Many of these conditions worsened or were complicated during the pandemic years. As COVID-19 recedes from the top of the mortality rankings, the challenge is to apply the same urgency to longstanding threats—expanding prevention, improving chronic disease management, and strengthening the public health system for the next crisis.

What to watch next

• Final 2024 mortality data: Provisional rankings will be confirmed (or modestly revised) as the year’s data are finalized.
• Winter respiratory season: The interplay among COVID-19, influenza, and RSV will shape hospital capacity and death patterns, especially for older adults and young children.
• Vaccine uptake trends: Uptake of updated COVID-19 and influenza vaccines among high-risk groups is a strong predictor of severe outcomes in the months ahead.
• Variant evolution: New lineages may alter transmissibility, immune escape, or severity, underscoring the need for surveillance and rapid response.

Bottom line

COVID-19 dropping out of the U.S. top 10 causes of death in 2024 is a meaningful sign of progress driven by immunity, better treatments, and public health adaptations. It is not a signal to ignore the virus. Sustaining and extending this progress—through vaccination, timely treatment, and targeted protections for those at highest risk—can keep severe illness uncommon, protect health system capacity, and continue to move the nation toward a steadier equilibrium with respiratory threats.